Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HALONASDAQ:NBIXNASDAQ:RGENNASDAQ:SGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHALOHalozyme Therapeutics$52.81-0.6%$56.73$42.01▼$70.51$6.55B1.191.66 million shs5.66 million shsNBIXNeurocrine Biosciences$126.55-0.6%$115.84$84.23▼$157.98$12.60B0.241.15 million shs1.58 million shsRGENRepligen$118.85+1.1%$128.71$102.97▼$182.52$6.60B1.1734,228 shs770,906 shsSGENSeagen$228.74$228.74$123.77▼$228.96$42.93B0.321.48 million shs86 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHALOHalozyme Therapeutics-0.64%-2.17%-2.08%-18.95%+5.05%NBIXNeurocrine Biosciences-0.60%+1.74%+4.97%+13.07%-3.29%RGENRepligen+1.11%-6.80%-1.13%-15.12%-3.37%SGENSeagen0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHALOHalozyme Therapeutics4.8705 of 5 stars3.12.00.04.42.92.54.4NBIXNeurocrine Biosciences4.7538 of 5 stars4.43.00.02.92.62.51.9RGENRepligen4.6472 of 5 stars4.31.00.04.52.91.71.9SGENSeagenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHALOHalozyme Therapeutics 2.17Hold$61.9017.21% UpsideNBIXNeurocrine Biosciences 2.86Moderate Buy$162.0028.01% UpsideRGENRepligen 2.69Moderate Buy$173.2545.77% UpsideSGENSeagen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SGEN, NBIX, RGEN, and HALO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025NBIXNeurocrine BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$145.005/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/14/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.005/13/2025HALOHalozyme TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/13/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform$47.005/7/2025HALOHalozyme TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2025HALOHalozyme TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $65.005/6/2025NBIXNeurocrine BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/6/2025NBIXNeurocrine BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$137.00 ➝ $145.005/6/2025NBIXNeurocrine BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$160.00 ➝ $154.005/6/2025NBIXNeurocrine BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$137.00 ➝ $152.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHALOHalozyme Therapeutics$1.02B6.41$4.62 per share11.42$2.86 per share18.47NBIXNeurocrine Biosciences$2.36B5.32$3.36 per share37.67$25.58 per share4.95RGENRepligen$650.43M10.27$3.14 per share37.83$35.21 per share3.38SGENSeagen$2.30B18.66N/AN/A$15.10 per share15.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHALOHalozyme Therapeutics$444.09M$3.7614.058.490.3544.76%136.91%26.05%8/5/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$2.9542.9019.561.3112.68%11.81%8.59%7/30/2025 (Estimated)RGENRepligen-$25.51M-$0.45N/A50.363.37-3.93%4.53%3.17%7/29/2025 (Estimated)SGENSeagen-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/ALatest SGEN, NBIX, RGEN, and HALO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 million5/5/2025Q1 2025NBIXNeurocrine Biosciences$0.70$0.08-$0.62$0.08$587.06 million$572.60 million4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ASGENSeagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHALOHalozyme Therapeutics3.138.397.30NBIXNeurocrine BiosciencesN/A3.133.02RGENRepligen0.276.795.79SGENSeagenN/A2.672.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHALOHalozyme Therapeutics97.79%NBIXNeurocrine Biosciences92.59%RGENRepligen97.64%SGENSeagen84.26%Insider OwnershipCompanyInsider OwnershipHALOHalozyme Therapeutics2.40%NBIXNeurocrine Biosciences4.80%RGENRepligen1.20%SGENSeagen25.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableNBIXNeurocrine Biosciences1,80098.97 million94.22 millionOptionableRGENRepligen1,77856.18 million55.51 millionOptionableSGENSeagen3,256187.70 million139.08 millionOptionableSGEN, NBIX, RGEN, and HALO HeadlinesRecent News About These CompaniesTrial win sets up new use for Astellas, Seagen's Padcev in bladder cancerMarch 16, 2025 | pharmaphorum.comMerck in "advanced talks" for $40bn Seagen bid; reportMarch 7, 2025 | pharmaphorum.comSeagen posts breast cancer win ahead of Pfizer takeoverFebruary 23, 2025 | pharmaphorum.comIs Merck planning a $30bn-plus move for Seagen?December 6, 2024 | pharmaphorum.comPfizer raises guidance as COVID franchise drives Q3 beatOctober 30, 2024 | seekingalpha.comPfizer Delivers Knockout Q3 Earnings Results, But Investors Are UnimpressedOctober 30, 2024 | seekingalpha.comFranklin Biotechnology Discovery COctober 5, 2024 | morningstar.comSeagen wins Enhertu patent dispute with Daiichi SankyoJuly 20, 2024 | pharmaphorum.comPfizer: Turning The Corner (Rating Upgrade)May 27, 2024 | seekingalpha.comTwo Brothers, a Big Biotech Bet and an $8 Billion PayoutApril 13, 2024 | wsj.comHER2 heats up as Seagen licenses RemeGen ADC for $2.6bnApril 2, 2024 | pharmaphorum.comRon Baron Portfolio Magic: Building Your Financial FutureMarch 20, 2024 | msn.comBailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving marketsMarch 13, 2024 | msn.comPfizer shutting down Seagen's $350M construction project in EverettMarch 1, 2024 | bizjournals.comNeuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk SaysFebruary 24, 2024 | finance.yahoo.comMRNA Feb 2024 64.000 putFebruary 23, 2024 | finance.yahoo.comMRNA Feb 2024 77.000 callFebruary 23, 2024 | finance.yahoo.comPfizer adds bull at Guggenheim on ex-COVID prospectsFebruary 23, 2024 | msn.comMRNA Feb 2024 67.000 putFebruary 22, 2024 | finance.yahoo.comPfizer touts cancer efforts in first Super Bowl commercialFebruary 12, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeMeta's Institutional & Insider Data Fuels Bulls Despite DisparityBy Leo Miller | May 28, 2025View Meta's Institutional & Insider Data Fuels Bulls Despite DisparitySGEN, NBIX, RGEN, and HALO Company DescriptionsHalozyme Therapeutics NASDAQ:HALO$52.81 -0.34 (-0.64%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$52.83 +0.02 (+0.04%) As of 06/20/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Neurocrine Biosciences NASDAQ:NBIX$126.55 -0.76 (-0.60%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$127.32 +0.77 (+0.61%) As of 06/20/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Repligen NASDAQ:RGEN$118.85 +1.31 (+1.11%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$118.84 0.00 (0.00%) As of 06/20/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Seagen NASDAQ:SGENSeagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
